{"id":"menacwy-single-dose-paracetamol","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain"},{"rate":null,"effect":"Injection site erythema"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MenACWY works by presenting polysaccharide antigens from four meningococcal serogroups conjugated to a protein carrier, triggering both T-cell and B-cell immune responses that generate protective antibodies. Paracetamol is included as a co-medication to reduce post-vaccination fever and systemic symptoms, potentially improving tolerability and compliance in the study population.","oneSentence":"MenACWY is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, W, and Y, while paracetamol is co-administered to manage potential fever and discomfort from vaccination.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:20:41.167Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y"}]},"trialDetails":[{"nctId":"NCT04324606","phase":"PHASE1, PHASE2","title":"A Study of a Candidate COVID-19 Vaccine (COV001)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2020-04-23","conditions":"Coronavirus","enrollment":1077},{"nctId":"NCT04536051","phase":"PHASE3","title":"A Study of a Candidate COVID-19 Vaccine (COV003)","status":"UNKNOWN","sponsor":"University of Oxford","startDate":"2020-06-02","conditions":"Coronavirus","enrollment":10300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MenACWY single dose + paracetamol","genericName":"MenACWY single dose + paracetamol","companyName":"University of Oxford","companyId":"university-of-oxford","modality":"Biologic","firstApprovalDate":"","aiSummary":"MenACWY is a vaccine used to protect against meningococcal disease, and it has been studied in the context of COVID-19 as part of a clinical trial (NCT04324606) at the University of Oxford. In this trial, MenACWY was administered as a single dose, and participants were also given paracetamol.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}